We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Silence Therapeutics announced that it has achieved another research milestone as part of its ongoing RNAi collaboration with Mallinckrodt plc for complement-mediated diseases, triggering a further $2.0 million payment to Silence.